http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
UNITY Biotechnology Announces Exclusive License Agreement with Jocasta Neuroscience to Continue Development of α-Klotho Program
-
UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates
-
UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology (UBX) Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease
-
UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease
-
UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference
-
UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular E
-
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates
-
UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases
-
UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
-
UNITY Biotechnology Reports Granting of New Employment Inducement Award
-
UNITY Biotechnology Announces Appointment of Alexander Nguyen as General Counsel
-
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology Appoints Mike Sapieha, Ph.D., as Chief Scientific Advisor
-
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
-
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O’Neill, M.B., to the Board of Directors
-
UNITY Biotechnology, Inc. Reports Third Quarter 2020 Financial Results and Clinical Program Updates
-
UNITY Biotechnology (UBX) Reports First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
-
UNITY Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema
-
UNITY Biotechnology (UBX) Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
-
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology
-
UNITY Biotechnology to Participate in Upcoming September Investor Conferences
-
UNITY Biotechnology (UBX) Announces Appointment of Lynne Sullivan as CFO
-
UNITY Biotechnology Announces Appointment of Lynne Sullivan as Chief Financial Officer
-
UNITY Biotechnology (UBX) Reports 12-Wk Data from UBX101 Phase 2 Clinical Study in Patients w/ Osteoarthritis of the Knee Painful
-
UNITY Biotechnology Announces 12-week data from UBX0101 Phase 2 Clinical Study in Patients with Painful Osteoarthritis of the Knee
-
UNITY Biotechnology Announces $80M Debt Financing From Hercules Capital
-
UNITY Biotechnology, Inc. Reports Second Quarter 2020 Financial Results and Clinical Program Updates
-
UPDATE – UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
-
UNITY Biotechnology, Inc. to Announce Second Quarter 2020 Financial Results
-
UNITY Biotechnology (UBX) Announces CFO Transition
-
UNITY Biotechnology Announces CFO Transition
-
UNITY Biotechnology, Inc. Provides Updates on Lead Development Programs
-
UNITY Biotechnology to Participate in Fireside Chat at the Goldman Sachs 41st Annual Global Healthcare Conference
-
UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference
-
UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates
-
UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results

